Quarterly Activities/Appendix 4C Cash Flow Report

• Advanced DEP® HER2-Lu towards Phase 1 clinical study in Europe
• Increased equity in Petalion Therapeutics to 66%, securing majority ownership
• Received AUD $0.5 million licensing option fee from Radiopharm
• Completed $32 million fully underwritten entitlement offer
• Cash balance of $34.4 million as of 30 September 2026

Starpharma Holdings Ltd, an innovative biotechnology company, reported its quarterly activities and Appendix 4C for Q1 FY27. Key highlights include advancing DEP® HER2-Lu towards the first-in-human Phase 1 clinical study, submitting the Clinical Trial Application in Europe, and completing the manufacture of non-radiolabelled clinical material. Following quarter end, Starpharma increased its equity interest in Petalion Therapeutics from 22.5% to 66%, securing majority ownership and operational leadership of its FAP-targeted DEP® oncology program. The company also received a $0.5 million licensing option fee from Radiopharm Theranostics under their collaboration agreement. Starpharma completed a $32 million fully underwritten entitlement offer, strengthening its balance sheet. The company ended Q1 FY27 with a cash balance of $34.4 million, and a pro forma cash balance of $37.9 million including the $3.5 million R&D tax incentive received.